BG Medicine Inc (NASDAQ:BGMD) last released its earnings data on Thursday, March 20th. The company reported ($0.06) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.12) by $0.06. The company had revenue of $1.15 million for the quarter, compared to the consensus estimate of $1.10 million. BG Medicine, Inc. (NASDAQ:BGMD) stock opened at $1.27 in last session, and closed at $1.32, while the day range of BGMD stock is $1.25 – $1.37. The stock showed a positive weekly performance of 2.33%.
Synthetic Biologics Inc (NYSEMKT:SYN) cratered -30.95% after the company hosted a conference call yesterday to discuss in further detail the topline Phase II study results of Trimesta™ (oral estriol), which the Company is developing as a once-daily adjunctive oral treatment for relapsing-remitting multiple sclerosis (RRMS) in women. Synthetic Biologics Inc (NYSEMKT:SYN) stock opened at $1.46, in last session and closed at $1.30, by losing -9.41%. The 52 week range of is $0.95 – $3.64. Company’s market capitalization is $75.76million.
Shares in RXi Pharmaceuticals Corp (NASDAQ:RXII) got a big boost on Friday following news that a treatment for retinal scarring developed using the company’s RNAi technology was effective in reducing the connective tissue growth factor (CTGF) protein levels in the eyes of cynomolgus monkeys. RXi Pharmaceuticals Corp (NASDAQ:RXII) stock advanced 6.62% and finished the last session at $3.38. The EPS of the stock remained -3.77. Company’s market capitalization is $45.38million.
BioMarin Pharmaceutical, Inc. (NASDAQ:BMRN) on Thursday reported an 18.5 percent increase in first-quarter revenue from a year before, and the quarterly net loss improved by 4.3 percent. First-quarter revenues for the San Rafael-based developer of pharmaceutical for severe or life-threatening rare diseases were $151.5 million. Of that, $80.1 million came from the drug Naglazyme, up 15.4 percent from a year before; $45.2 million from Kuvan, 20.2 percent; $18.1 million from Aldurazyme; and $900,000 from newly approved Vimizim. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stock opened the session at $58.00, and closed the session at $57.70. The 52 week range of the BMRN stock remained $53.53 – $84.25 and the day range was $55.50 – $60.20.